JP2023501602A5 - - Google Patents
Info
- Publication number
- JP2023501602A5 JP2023501602A5 JP2022527773A JP2022527773A JP2023501602A5 JP 2023501602 A5 JP2023501602 A5 JP 2023501602A5 JP 2022527773 A JP2022527773 A JP 2022527773A JP 2022527773 A JP2022527773 A JP 2022527773A JP 2023501602 A5 JP2023501602 A5 JP 2023501602A5
- Authority
- JP
- Japan
- Prior art keywords
- human patient
- dose
- genetically modified
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934961P | 2019-11-13 | 2019-11-13 | |
| US62/934,961 | 2019-11-13 | ||
| US202063034552P | 2020-06-04 | 2020-06-04 | |
| US63/034,552 | 2020-06-04 | ||
| PCT/IB2020/060719 WO2021095010A1 (en) | 2019-11-13 | 2020-11-13 | Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501602A JP2023501602A (ja) | 2023-01-18 |
| JP2023501602A5 true JP2023501602A5 (enExample) | 2023-11-08 |
Family
ID=73695085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527773A Pending JP2023501602A (ja) | 2019-11-13 | 2020-11-13 | Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する腎細胞癌（ｒｃｃ）療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387572A1 (enExample) |
| EP (1) | EP4058053A1 (enExample) |
| JP (1) | JP2023501602A (enExample) |
| KR (1) | KR20220100913A (enExample) |
| CN (1) | CN114929267A (enExample) |
| AU (1) | AU2020383021A1 (enExample) |
| BR (1) | BR112022009204A2 (enExample) |
| CA (1) | CA3158110A1 (enExample) |
| IL (1) | IL292468A (enExample) |
| MX (1) | MX2022005821A (enExample) |
| WO (1) | WO2021095010A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| KR20220101128A (ko) * | 2019-11-13 | 2022-07-19 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법 |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| EP4305153A1 (en) * | 2021-03-09 | 2024-01-17 | CRISPR Therapeutics AG | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
| US20220378829A1 (en) * | 2021-05-12 | 2022-12-01 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
| WO2023072307A1 (zh) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用 |
| EP4482872A4 (en) * | 2022-03-07 | 2026-03-18 | Nkarta Inc | Multiplex gene-edited cells for CD70-led cancer immunotherapy |
| KR20250109947A (ko) | 2024-01-11 | 2025-07-18 | 재단법인 아산사회복지재단 | 흉선 세포 또는 흉선 상피세포를 유효성분으로 포함하는 암 예방용 약학적 조성물 |
| CN117844811A (zh) * | 2024-03-08 | 2024-04-09 | 上海恒润达生生物科技股份有限公司 | 靶向敲除CD70基因的sgRNA组合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11352631B2 (en) * | 2015-12-18 | 2022-06-07 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR20220101128A (ko) * | 2019-11-13 | 2022-07-19 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법 |
-
2020
- 2020-11-13 KR KR1020227019520A patent/KR20220100913A/ko not_active Withdrawn
- 2020-11-13 AU AU2020383021A patent/AU2020383021A1/en not_active Abandoned
- 2020-11-13 CA CA3158110A patent/CA3158110A1/en active Pending
- 2020-11-13 BR BR112022009204A patent/BR112022009204A2/pt not_active Application Discontinuation
- 2020-11-13 IL IL292468A patent/IL292468A/en unknown
- 2020-11-13 MX MX2022005821A patent/MX2022005821A/es unknown
- 2020-11-13 CN CN202080090978.5A patent/CN114929267A/zh active Pending
- 2020-11-13 EP EP20817494.6A patent/EP4058053A1/en not_active Withdrawn
- 2020-11-13 JP JP2022527773A patent/JP2023501602A/ja active Pending
- 2020-11-13 WO PCT/IB2020/060719 patent/WO2021095010A1/en not_active Ceased
- 2020-11-13 US US17/776,860 patent/US20220387572A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501611A5 (enExample) | ||
| Fujiwara et al. | CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment | |
| Daei Sorkhabi et al. | The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies | |
| EP3858388B1 (en) | Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd | |
| US20250320306A1 (en) | Methods for production of tissue resident memory-like t cells and use thereof | |
| US20220195460A1 (en) | Retroviral vector having immune-stimulating activity | |
| ES3032321T3 (en) | Toxicity management for anti-tumor activity of cars | |
| AU2013329083C1 (en) | Enhancement of the immune response | |
| KR20150063145A (ko) | 면역치료용 조성물 및 방법 | |
| JP2018512161A (ja) | 修正ガンマデルタｔ細胞およびその使用 | |
| JP2022531185A5 (enExample) | ||
| Fan et al. | Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors | |
| US20230340052A1 (en) | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof | |
| JP2022546539A (ja) | 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム | |
| Amitrano et al. | Metabolic challenges in anticancer CD8 T cell functions | |
| Zhang et al. | Current and future perspectives of chimeric antigen receptors against glioblastoma | |
| Wang et al. | BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma | |
| Noubissi et al. | Mechanisms of cell fusion in cancer | |
| Mariniello et al. | CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives | |
| WO2020149258A1 (ja) | 免疫チェックポイント阻害剤 | |
| BV | Prospect of chimeric antigen receptor T-cell therapy for cancer | |
| CN114364390A (zh) | 用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物 | |
| Zheng et al. | Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects | |
| US20250205336A1 (en) | Targeting the pvr axis using car t cell therapy and combinations | |
| Stahl | Chimeric antigen receptor T-cell therapy in cancer |